Your browser doesn't support javascript.
loading
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Hampel, Paul J; Rabe, Kari G; Call, Timothy G; Ding, Wei; Leis, Jose F; Kenderian, Saad S; Muchtar, Eli; Wang, Yucai; Koehler, Amber B; Parrondo, Ricardo; Schwager, Susan M; Shi, Min; Braggio, Esteban; Slager, Susan L; Kay, Neil E; Parikh, Sameer A.
Afiliación
  • Hampel PJ; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Rabe KG; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Call TG; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Ding W; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Leis JF; Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
  • Kenderian SS; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Muchtar E; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Wang Y; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Koehler AB; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Parrondo R; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Schwager SM; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Shi M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Braggio E; Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
  • Slager SL; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Kay NE; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Parikh SA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Br J Haematol ; 199(2): 239-244, 2022 10.
Article en En | MEDLINE | ID: mdl-35841338
ABSTRACT
Patients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax-based treatments (double-refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment-free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax-naïve) were 23.7 and 47.1 months respectively. In 11 patients with double-refractory CLL, the median treatment-free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos